MethodsSixty six patients with clinical activity index CAI 10–18 were randomly assigned to intensive GMA with the Adacolumn, at two sessions/week in the first 3 weeks and then one session/week for up to 10 sessions (n = 33) or iv PSL, 40–60 mg/day for 5–10 days. This study compared the efficacy and safety of intensive GMA with intensive intravenous (iv) prednisolone (PSL) in patients with severe UC. 1Department of Medicine, Hamamatsu University 2Fujueda General Hospital 3Hamamatsu Medical Centre 4Hamamatsu Rosai Hospital 5Hamamatsu Insurance Hospital 6Japan Immunoresearch Laboratories, JapanīackgroundRecently several uncontrolled studies have reported on the efficacy of adsorptive depletion of peripheral blood granulocytes and monocytes/macrophages (GMA) in patients with moderate or severe ulcerative colitis (UC). Genotype analysis reveals borderline increased heterozygosity in Scottish IBD compared with HC (p = 0.049, RR 1.37).Ġ03 Intensive granulocyte and monocyte apheresis versus intravenous prednisolone in patients with severe ulcerative colitis: a multicentre randomised controlled study ResultsIn all Scottish IBD cases there was a non‐significant increase in the allelic frequency and carriage rate of the variant A allele compared with HC (see table table). Genotyping for the 1706G→A variant was carried out using the Taqman system for allelic discrimination.
The Scottish IBD population was 100% white with a mean age of diagnosis of 28.1 years. Methods523 UC, 442 CD, and 351 healthy controls (HC) were studied. We have assessed the contribution of the 1706G→A polymorphism in determining susceptibility and disease phenotype in UC and Crohn's disease (CD). The protein is a key immunological signal, fundamental to the pathogenesis of inflammatory bowel disease (IBD). The CCL20 gene is located on chromosome 2q36.3 in a short haplotype block containing no other genes (see ). 1 These data have yet to be replicated in other populations. 1 In a South Korean population, the 1706G→A polymorphism in the CCL20 promoter was strongly associated with susceptibility to UC (p<0.0001). IntroductionRecent data have suggested that variants of the CCL20 gene are associated with susceptibility to ulcerative colitis (UC). GI Unit, Molecular Medicine Centre, University of Edinburgh, UK We confirm the association with HLA‐DRB1*0103 and further demonstrate that this allele may predict disease course.Ġ02 Analysis of CCL20 variants in IBD provides further evidence for genetic heterogeneity in disease susceptibilityĬ. We confirmed the association with DRB1*0103 (14.7% cases v 2.7% controls p = 5.5×10 −9 RR = 3.2) and report the novel association of this allele with time to first surgical event (Log Rank p = 0.002) and time to first “severity event” (resection/diversion ileostomy/Infliximab) (p = 0.001).ĬonclusionsThis study reports the clinical manifestations of isolated colonic CD. 12% of the entire cohort received ⩾1 Infliximab infusion and 19% underwent colonic resection for severe disease (cumulative risk at 2 years, 10.6% 5 years, 17.1% 10 years, 32.8%). Stricturing colonic disease was noted in 10% of patients.
29.4% and 14.0% reported a family history (1st or 2nd degree) of CD and UC respectively. The mean age at diagnosis was 30.7 years. Results136 (10.3%) patients were classified with L2 disease after a median follow up of 10.8 years (range 1.4–39.8). HLA genotyping was performed using PCR‐SSP. Only patients with a normal small bowel enema (70%), ileoscopy alone (30%), or both (20%) were included. MethodsPatients with L2 disease were identified from a database of 1318 CD patients. (2) To confirm the association with HLA‐DRB1*0103, reported in smaller cohorts, and to investigate its role in predicting disease course and need for surgery. Little is known about the epidemiology and natural history of isolated CD of the colon (Montreal Classification L2) because most studies have not accurately distinguished L2 from 元 disease (ileo‐caecal).Īims(1) To describe the clinical features and natural history of isolated colonic CD in a rigorously characterised patient cohort.
Departments of 1Gastroenterology, 2Colorectal Surgery, 3Histopathology, University of Oxford, Radcliffe Infirmary, Oxford OX2 6QX, UKīackgroundClinical, serological, and molecular data support the existence of discrete subsets of Crohn's disease (CD) defined by location of disease. 001 Clinical and molecular characteristics of isolated colonic Crohn's disease
0 kommentar(er)
